placeholder
A new test is changing cancer treatment and has implications for other illnesses, too.
After a young man with acute leukemia was treated successfully with traditional chemotherapy, he found himself facing a tough decision. He could stay on chemo and face the high risk of relapse associated with his particular disease, or he could undergo a blood or bone marrow transplant, which would offer the best chance of a cure but put him at risk for severe complications.
A blood test known as a "liquid biopsy" could help doctors track a shifty type of lung cancer without the need for invasive procedures, an international team of researchers says.
The New York Times reports on the recent advancements in liquid biopsy research, which suggest this kind of test could be an alternative to current methods for evaluating treatment response and monitoring disease status. The report also highlights the recent study published in Lancet Oncology, which showed that analysis of circulating tumor DNA using Adaptive’s clonoSEQ™ MRD test predicted relapse in patients with diffuse large B-cell lymphoma (DLBCL).
Last month Washington Gov. Jay Inslee and national leader Rev. Jesse Jackson came together on the Microsoft campus to declare that the future of our economy relies on preparing more students—especially minorities and women—for STEM (Science, Technology, Engineering, and Math) jobs.
NEW YORK (GenomeWeb) – Researchers at Columbia University have used an immune sequencing strategy to describe a mechanism responsible for kidney transplant tolerance.
Using immune sequencing services from Adaptive Biotechnologies, the team discovered a set of patient-specific T cell receptors that react to the donor organ and disappear over time in those patients who do not reject the organ. They published their results this week in Science Translational Medicine.
Adaptive Biotechnologies used to have a game room in its Eastlake office, but it has been overtaken with freezers full of DNA.
That's just one of the not-so-typical pain points immunosequencing company is facing as it continues to grow.
The company just expanded its space — nearly tripling the square footage of its lab and office space to 35,000 square feet. Adaptive has an option for 25,000 more square feet if the expansion and growth continues.
Listen to an on-demand webcast of the 2015 J.P. Morgan Healthcare Conference panel discussion, Harnessing the Power of Next Gen Sequencing - The View from the Industry. The esteemed panel includes Chad Robins, CEO of Adaptive Biotechnologies along with executives from inVitae, Regeneron Laboratories, and 10X Genomics. First time visitors to the J.P. Morgan Healthcare Conference site will need to register (no charge) before viewing the webcast.
KUWO radio host, Marcie Sillman, talks to science writer Luke Timmerman about the growth of a Seattle biotech company, Adaptive Biotechnologies, and what it means for the city's biotechnology industry.
By the end of this winter, as many as 150 million people in the US may have received this season's flu vaccine, but not all of them will be protected from catching the flu. In fact, up to 40% of people over the age of 60 won't even make antibodies in responses to the vaccine1. Immunologist Mark Davis is trying to understand why.
Twice in the past year, Adaptive Biotechnologies raised a truckload of cash. The first time, the company invested in its cutting-edge immune system sequencing. This time, it is using the loot to acquire a competitor, and hatch new plans to build a company with potentially profound influence over the diagnosis and treatment of infectious diseases, autoimmunity, and cancer.
Luke Timmerman, national biotech editor for Xconomy discusses the latest news in biotechnology.
